Merck/Lundbeck Gaboxadol NDA Planned For 2007; Merck Gets Fourth Phase III NME
This article was originally published in The Pink Sheet Daily
Executive Summary
The $270 mil. licensing deal with Lundbeck will help boost Merck's pipeline after two significant late-stage setbacks in 2003. The GABA-A receptor agonist gaboxadol would be Merck's entry into the sleep disorder market.
You may also be interested in...
Merck And Lundbeck Discontinue Gaboxadol Development For Insomnia
Phase III trials for the GABA-A receptor antagonist do not support further development, the firms state.
Merck And Lundbeck Discontinue Gaboxadol Development For Insomnia
Phase III trials for the GABA-A receptor antagonist do not support further development, the firms state.
Merck Gaboxadol Submission Delayed Until Mid-2007
Merck and its partner Lundbeck will not submit an NDA for the sleep aid in the first quarter, as previously planned.